The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Immune Checkpoint Inhibitors & Immune-Related Adverse Events

Immune Checkpoint Inhibitors & Immune-Related Adverse Events

September 20, 2018 • By Priya Chokshi, MD, Roberta Seidman, MD, Noah Levit, PhD, MD, & Steven E. Carsons, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Noah Levit, PhD, MD, is a third-year post­graduate dermatology resident at the University of Colorado, Anschutz Medical Campus. His interests include cutaneous toxicity, oncodermatology, and improving access to dermatologic care for cancer patients

You Might Also Like
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
  • Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
Explore This Issue
September 2018

Steven Carsons, MD, is chief of the Division of Rheumatology, Allergy and Immunology and program director of the rheumatology fellowship program at NYU Winthrop Hospital in New York.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Acknowledgments

The authors would like to thank the following: Elise Belilos, MD, Rheumatology Division, NYU Winthrop Hospital; Gary Rosenblum, MD, Rheumatology Division, NYU Winthrop Hospital; Kristina Belostocki, MD, Rheumatology Division, NYU Winthrop Hospital; Eun Ji Kwon, MD, Dermpath Diagnostics Pathology Associates

References

  1. McDermott D, Atkins M. PD-1 as a potential target in cancer therapy. Cancer Med. 2013 Oct;2(5):662–673.
  2. Suarez-Almazor M, Kim S, Abdel-Wahab N, Diab A. Review: Immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol. 2017 Apr;69(4):687–699.
  3. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015 Dec;26(12):2375–2391.
  4. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016 Jun;60:210–225.
  5. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016 Mar;44:51–60.
  6. Gaillard S, Secord A, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. 2016 Nov 24;3:11.
  7. Min KJ, Ouh YT, Hong HR, et al. Muscle weakness and myalgia as the initial presentation of serous ovarian carcinoma: A case report. J Ovarian Res. 2014 Apr 23;7:43.
  8. Whitmore SE, Rosenshein NB, Provost TT. Ovarian cancer in patients with dermatomyositis. Medicine (Baltimore). 1994 May;73(3):153–160.
  9. Levine SM. Cancer and myositis: New insights into an old association. Curr Opin Rheumatol. 2006 Nov;18(6):620–624.
  10. Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med. 1992 Feb 6;326(6):363–367.
  11. Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016 Feb 18;374(7):664–669.
  12. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005 Dec 12–26;165(22):2671–2676.
  13. Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016 Aug 16;4(50):1–11.
  14. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016 Nov 3;375(18):1749–1755.
  15. Tarrio ML, Grabie N, Bu DX, et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol. 2012 May 15;188(10):4876–4884.
  16. Lucas JA, Menke J, Rabacal WA, et al. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol. 2008 Aug 15;181(4):2513–2521.
  17. Goldinger SM, Stieger P, Meier B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016 Aug 15;22(16):4023–4029.
  18. Lo JA, Fisher DE, Flaherty KT. Prognostic significance of cutaneous adverse events associated with pemrolizumab therapy. JAMA Oncol. 2015 Dec;1(9):1340–1341.
  19. Ziemer M, Koukoulioti E, Beyer S, et al. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol. 2017 Mar;66(3):657–665.
  20. Johncilla M, Misdraji J, Pratt DS, et al. Ipiimumab-associated hepatitis: Imaging and clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015 Aug;39:1075–1084.
  21. Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016 Jul;107(7):1055–1058.
  22. Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient withmelanoma. Japanese J Clin Onc. 2016 Jan;46(1):86–88.

Pages: 1 2 3 4 5 6 7 8 9 10 | Single Page

Filed Under: Conditions, Drug Updates, Systemic Inflammatory Syndromes Tagged With: immune-related adverse events, irAEs, myositis, nivolumabIssue: September 2018

You Might Also Like:
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
  • Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease
  • Rheumatology Case Report: Immune-Related Aortitis Associated with Ipilimumab

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)